311 related articles for article (PubMed ID: 21984370)
21. The redox biology of schistosome parasites and applications for drug development.
Huang HH; Rigouin C; Williams DL
Curr Pharm Des; 2012; 18(24):3595-611. PubMed ID: 22607149
[TBL] [Abstract][Full Text] [Related]
22. Experiences with praziquantel against Schistosoma japonicum infection in the Philippines.
Noseñas JS; Santos AT; Blas BL; Tormis LC; Portillo GP; Poliquit OS; Papasin MC; Flores GS
Southeast Asian J Trop Med Public Health; 1984 Dec; 15(4):489-97. PubMed ID: 6398917
[No Abstract] [Full Text] [Related]
23. Efficacy of praziquantel and artemisinin derivatives for the treatment and prevention of human schistosomiasis: a systematic review and meta-analysis.
Liu R; Dong HF; Guo Y; Zhao QP; Jiang MS
Parasit Vectors; 2011 Oct; 4():201. PubMed ID: 22004571
[TBL] [Abstract][Full Text] [Related]
24. Toward organometallic antischistosomal drug candidates.
Hess J; Keiser J; Gasser G
Future Med Chem; 2015; 7(6):821-30. PubMed ID: 25996072
[TBL] [Abstract][Full Text] [Related]
25. Macromolecular bases of antischistosomal therapy.
Angelucci F; Miele AE; Boumis G; Brunori M; Dimastrogiovanni D; Bellelli A
Curr Top Med Chem; 2011; 11(16):2012-28. PubMed ID: 21619508
[TBL] [Abstract][Full Text] [Related]
26. Use of praziquantel for clinical treatment and morbidity control of schistosomiasis japonica in China: a review of 30 years' experience.
Chen MG
Acta Trop; 2005; 96(2-3):168-76. PubMed ID: 16125657
[TBL] [Abstract][Full Text] [Related]
27. Schistosoma japonicum-infected hamsters (Mesocricetus auratus) used as a model in experimental chemotherapy with praziquantel, artemether, and OZ compounds.
Xiao SH; Mei JY; Jiao PY
Parasitol Res; 2011 Feb; 108(2):431-7. PubMed ID: 20922422
[TBL] [Abstract][Full Text] [Related]
28. Chemotherapy for Fighting Schistosomiasis: Past, Present and Future.
Mäder P; Rennar GA; Ventura AMP; Grevelding CG; Schlitzer M
ChemMedChem; 2018 Nov; 13(22):2374-2389. PubMed ID: 30212614
[TBL] [Abstract][Full Text] [Related]
29. Praziquantel derivatives with antischistosomal activity: aromatic ring modification.
Wang ZX; Chen JL; Qiao C
Chem Biol Drug Des; 2013 Aug; 82(2):216-25. PubMed ID: 23617439
[TBL] [Abstract][Full Text] [Related]
30. Recent Advances in the Synthesis of Antischistosomal Drugs and Agents.
Liu LX; Li-Li J; Qiong C; Xiao-Lin F
Mini Rev Med Chem; 2017; 17(5):467-484. PubMed ID: 24251801
[TBL] [Abstract][Full Text] [Related]
31. The Journey to Discovering a Flatworm Target of Praziquantel: A Long TRP.
Park SK; Marchant JS
Trends Parasitol; 2020 Feb; 36(2):182-194. PubMed ID: 31787521
[TBL] [Abstract][Full Text] [Related]
32. Modulation of the antioxidant defence in different developmental stages of Schistosoma mansoni by praziquantel and artemether.
El-Bassiouni EA; Helmy MH; Saad EI; El-Nabi Kamel MA; Abdel-Meguid E; Hussein HS
Br J Biomed Sci; 2007; 64(4):168-74. PubMed ID: 18236739
[TBL] [Abstract][Full Text] [Related]
33. Praziquantel: its use in control of schistosomiasis in sub-Saharan Africa and current research needs.
Doenhoff MJ; Hagan P; Cioli D; Southgate V; Pica-Mattoccia L; Botros S; Coles G; Tchuem Tchuenté LA; Mbaye A; Engels D
Parasitology; 2009 Nov; 136(13):1825-35. PubMed ID: 19281637
[TBL] [Abstract][Full Text] [Related]
34. Schistosomiasis therapeutics: whats in the pipeline?
Trainor-Moss S; Mutapi F
Expert Rev Clin Pharmacol; 2016; 9(2):157-60. PubMed ID: 26508363
[TBL] [Abstract][Full Text] [Related]
35. Current progress in the development and use of artemether for chemoprophylaxis of major human schistosome parasites.
Utzinger J; Xiao S; Keiser J; Chen M; Zheng J; Tanner M
Curr Med Chem; 2001 Dec; 8(15):1841-60. PubMed ID: 11772354
[TBL] [Abstract][Full Text] [Related]
36. [Observations on the histopathological changes of Schistosoma japonicum and host liver caused by pyquiton in experimental chemotherapy (author's transl)].
Yang YQ; Yang HZ; Xiao SH; Shao BR; Tang XM; Zhu ZG; Zhang HX
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 1979 Sep; 1(1):7-12. PubMed ID: 262815
[No Abstract] [Full Text] [Related]
37. Current results in the clinical therapy of schistosomiasis mansoni.
Katz N
Rev Inst Med Trop Sao Paulo; 1980; 22(1 Suppl 4):8-17, 123-33. PubMed ID: 7006041
[No Abstract] [Full Text] [Related]
38. Piggy-backing the concept of cancer drugs for schistosomiasis treatment: a tangible perspective?
Dissous C; Grevelding CG
Trends Parasitol; 2011 Feb; 27(2):59-66. PubMed ID: 20920890
[TBL] [Abstract][Full Text] [Related]
39. Could we expect new praziquantel derivatives? A meta pharmacometrics/pharmacoinformatics analysis of all antischistosomal praziquantel derivatives found in the literature.
da Silva VBR; Boucherle B; El-Methni J; Hoffmann B; da Silva AL; Fortune A; de Lima MDCA; Thomas A
SAR QSAR Environ Res; 2019 Jun; 30(6):383-401. PubMed ID: 31144535
[TBL] [Abstract][Full Text] [Related]
40. Repurposing apoptosis-inducing cancer drugs to treat schistosomiasis.
Lee EF; Fairlie WD
Future Med Chem; 2015; 7(6):707-11. PubMed ID: 25996064
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
